Journals / Çocuk Dergisi / 2014 / Cilt: 14 - Sayı: 4

Optimizing Growth Hormone Therapy in Chilhood Growth Hormone Defiency

Çocukluk Çağı Büyüme Hormonu Eksikliğinde Büyüme Hormonu Tedavisinin Optimizasyonu

Pages
148–155
Publication Date
2014-10-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, optimal treatment of GHD has been evalua- ted in terms of targets of GH replacement therapy, factors affecting treatment response, growth response prediction models, assessment of insufficient treatment response, monitorization, and discontinuation of GH treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The diagnosis and treatment of growth hormone deficiency GHD are challenging issues with no clear-cut consensus on the diagnostic criteria and which children should be treated.
📊
Key Findings & Data:Optimal treatment of growth disorders depends on accurate definition of underlying etiology and identificati- on of realistic treatment targets.
💡
Conclusion & Impact:In this review, optimal treatment of GHD has been evalua- ted in terms of targets of GH replacement therapy, factors affecting treatment response, growth response prediction models, assessment of insufficient treatment response, monitorization, and discontinuation of GH treatment
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Büyüme hormonu eksikliği · büyüme hormonu tedavisi · tedavi optimizasyonu

Abstract

The diagnosis and treatment of growth hormone deficiency GHD are challenging issues with no clear-cut consensus on the diagnostic criteria and which children should be treated. Optimal treatment of growth disorders depends on accurate definition of underlying etiology and identificati- on of realistic treatment targets. Close follow up of treated patients in terms of efficacy and safety of treatment as well as evaluation of treatment response with identification of responsible factors and implementing appropriate dose adjustment in case of insufficient treatment response are critical factors in opimizing growth hormone GH therapy. In this review, optimal treatment of GHD has been evalua- ted in terms of targets of GH replacement therapy, factors affecting treatment response, growth response prediction models, assessment of insufficient treatment response, monitorization, and discontinuation of GH treatment

Özet

Büyüme hormonu eksikliğinde BHE tanı ve tedavi süreci oldukça zorlu olup, gerek tanı kriterleri gerekse hangi çocuklara tedavi verilmesi gerektiği konusunda henüz tam bir görüş birliği yoktur. Büyüme bozukluklarının optimal tedavisi etiyolojinin doğru tanılanması ve gerçekçi tedavi hedeflerinin belirlenmesi ile olası olup, tedavi altındaki hastaların etkililik ve güvenlilik açısından yakın izlemi, izlem sürecinde tedavi yanıtı değerlendirilerek yetersiz yanıt durumunda ilgili faktörlerin belirlenmesi ve uygun doz ayarlamalarının yapılması BH tedavisinin optimizas- yonunun kritik bileşenlerindendir. Bu derleme makalesin- de, büyüme hormonu BH yerine koyma tedavisi hedefleri ve tedavi yanıtını etkileyen faktörler, büyüme yanıtı öngörü modelleri, yetersiz tedavi yanıtının değerlendirilmesi, BH tedavisi izlemi ve BH tedavisinin kesilmesi açısından değerlendirilmektedir

🔖

Cite This Article

DARENDELİLER, F. (2014). Optimizing Growth Hormone Therapy in Chilhood Growth Hormone Defiency. Çocuk Dergisi, Cilt: 14 - Sayı: 4, 148–155. https://ajindex.com/articles/246814

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Hardin DS, Woo J, Butsch R, et al. Current prescribing practices and opinions about growth hormone therapy: results of a nationwide survey of paediatric endocrinologists. Clin Endocrinol (Oxf) 2007;66:85-94
  2. Darendeliler F. Growth hormone therapy in childhood: Evidence-based approach. J Child 2009;9:158-66
  3. Bang P, Ahmed SF, Argente J, et al. Identification and management of poor response to growth-promoting therapy in children with short stature. Clin Endocrinol (Oxf) 2012;77:169- 81. Review.
  4. Darendeliler F, Lindberg A, Wilton P. Response to growth hormone treatment in isolated growth hormone deficiency versus multiple pituitary hormone deficiency. Horm Res Paediatr 2011;76: 42-6.
  5. Rose S. Optimal therapy of growth hormone deficiency in the child and adolescent. Eur Endocrinol 2011;7:40-6.
  6. Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. J Pediatr 1995;127:857-67.
  7. American Academy of Pediatrics Committee on Drugs and Committee on Bioethics. Considerations related to the use of recombinant human growth hormone in children. Pediatrics 1997;99:122-9.
  8. Saggese G, Ranke MB, Saenger P, et al. Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27-28 March 1998. Horm Res 1998;50:320-40.
  9. GH Research Society. Consesus Guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH research society. J Clin Endocrinol Metab 2000;85:3990-3
  10. Wilson TA, Rose SR, Cohen P, et al. Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003; 143:415-21.
  11. Lee PA, Chernausek SD, Hokken-Koelega AC, et al. International Small for Gestational Age Advisory Board. International Small for Gestational Age Advisory Board consensus develo